Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone

Leukemia and Lymphoma

Volumn 56, Issue 2, 2015, Pages 407-414

  Sun, Haowei Linda ^a   Atenafu, Eshetu G ^b   Yeboah, Elizabeth ^c   Reece, Donna E ^b   Trudel, Suzanne ^b   Kukreti, Vishal ^b   Masih Khan, Esther ^d   Winter, Andrew ^b   Chen, Christine ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Granulocyte colony stimulating factor; Infections; Lenalidomide plus dexamethasone; Neutropenia; Relapsed or refractory multiple myeloma

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; THALIDOMIDE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOODSTREAM INFECTION; CAUSE OF DEATH; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COMPASSIONATE USE; CYTOPENIA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENTEROCOCCAL INFECTION; ESCHERICHIA COLI INFECTION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INFECTION; INFLUENZA; INTENSIVE CARE; KLEBSIELLA INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE MYELOMA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; SURVIVAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG RESISTANCE; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; RETROSPECTIVE STUDIES; THALIDOMIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923924413     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.915544     Document Type: Article

References (24)

1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520
2. Dimopoulos M, Spencer A, Attal M, et al. Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132
3. Weber DM, Chen C, Niesvizky R, et al. Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133-2142
4. Dimopoulos MA, Hussein M, Swem AS, et al. Long-term outcomes and safety of continuous lenalidomide plus dexamethasone (Len Dex) treatment in patients (Pts) with relapsed or refractory multiple myeloma (RRMM). Blood 2011; 118(Suppl. 1): Abstract 2929
5. H arousseau J L, Dimopoulos M A, Wang M, et al. B etter quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 2010; 95: 1738-1744
6. Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 2009; 146: 164-170
7. L onial S, Baz R, Swern A S, et al. N eutropenia is a predictable and early event in aff ected patients with relapsed/refractory multiple myeloma treated with lenalidomide in combination with dexamethasone. Blood 2009; 114 (Suppl. 1): Abstract 2879
8. N ational Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE) [Internet]. 2006. Available from: http://ctep.info.nih.gov/protocolDevelopment/electronic- applications/docs/ct
9. Durie BG, Harousseau JL, Mignel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473
10. D imopoulos M A, Chen C, Spencer A, et al. L ong-term followup on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009; 23: 2147-2152
11. Reece DE, Masih-Khan E, Goswami RS, et al. Incidence and characteristics of secondary myelodysplastic syndrome developing during lenalidomide-based regimens in relapsed and/or refractory multiple myeloma patients. Blood 2010; 116(Suppl. 1): Abstract 1877
12. Mateos MV, Garc í a-Sanz R, Colado E, et al. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy? Br J Haematol 2008; 140: 324-326
13. Dimopoulos MA, Hussein M, Swern AS, et al. Full dose of lenalidomide for 12 months followed by a lower maintenance dose improves progression-free survival in patients with relapsed/refractory multiple myeloma. Blood 2009; 112(Suppl. 1): Abstract 2874
14. Richardson P, Jagannath S, Hussein M, et al. Safety and effi cacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009; 114: 772-778
15. Avet-Loiseau H, Soulier J, Fermand JP, et al. IFM and MAG groups. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 2010; 24: 623-628
16. Chanan-Khan AA, Dimopoulos MA, Weber DM, et al. Lenalidomide (L) in combination with dexamethasone (D) signifi cantly improves time to progression (TTP) in non-stem cell transplant patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM): analysis from MM-009 and MM-010 randomized phase III clinical trials
17. . Blood 2006; 108(Suppl. 1): Abstract 3554
18. B az R, Lonial S, Hussein M, et al. L enalidomide (LEN) therapy in combination with dexamethasone (DEX) is associated with a low incidence of viral infections. Blood 2010; 116(Suppl. 1): Abstract 1950
19. Rajkumar SV, Jacobus S, Callander NS, et al. Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomized controlled trial. Lancet Oncol 2010; 11: 29-37
20. C linicalTrials.gov [Internet]. Romiplostim in increasing low platelet counts in patients with multiple myeloma receiving chemotherapy (NCT01676961). New York University School of Medicine. October 2013. Available from: http://clinicaltrials.gov
21. Wang E S, Lyons R M, Larson R A, et al. A randomized, doubleblind, placebo-controlled phase 2 study evaluating the effi cacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. J Hematol Oncol 2012; 5: 71
22. ClinicalTrials.gov [Internet]. Filgrastim in treating patients with bortezomib-, carfi lzomib-, or IMID-refractory multiple myeloma (NCT01537861). Washington University School of Medicine. August 2013. Available from: http://clinicaltrials.gov
23. Pal R, Monaghan SA, Hassett AC, et al. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood 2010; 115: 605-614
24. Reece D, Kouroukis T, Leblanc R, et al. Practical approaches to the use of lenalidomide in multiple myeloma: a Canadian consensus. Adv Hematol 2012; 2012: 621958.